Intermountain Healthcare

Before broad implementation, the healthcare system will gauge the feasibility of the screening program, patient impact, and cost-benefit in a pilot phase.

Hospitals and philanthropies in the US are forming their own drug company called Civica Rx.

Researchers can apply to receive $100,000 in matched funds from Intermountain to cover project costs related to high-throughput genomic sequencing.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

The health system hopes to pair the data with nearly three decades worth of electronic health records as well as medical histories provided by contributors.

Following several Sync for Genes pilots, FHIR Genomics advocates are pushing for adoption of their standard to make omics data compatible with EHRs.

Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.

The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.

The researchers now plan to apply the linked-read technology to additional cancer samples as well as other disease cohorts with suspected structural variants.

Navican Raises $15M

The Intermountain spinout will use the Series A financing to commercialize and expand its precision cancer care offering, including the TheraMap solution. 

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.